Biovaxys Technology Number Of Employees vs. Book Value Per Share
| BVAXF Stock | USD 0.04 0.0003 0.71% |
For Biovaxys Technology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biovaxys Technology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biovaxys Technology Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biovaxys Technology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biovaxys Technology Corp over time as well as its relative position and ranking within its peers.
Biovaxys |
Biovaxys Technology Corp Book Value Per Share vs. Number Of Employees Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Biovaxys Technology's current stock value. Our valuation model uses many indicators to compare Biovaxys Technology value to that of its competitors to determine the firm's financial worth. Biovaxys Technology Corp is rated fifth in number of employees category among its peers. It is rated below average in book value per share category among its peers . The ratio of Number Of Employees to Book Value Per Share for Biovaxys Technology Corp is about 269.84 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biovaxys Technology's earnings, one of the primary drivers of an investment's value.Biovaxys Number Of Employees vs. Competition
Biovaxys Technology Corp is rated fifth in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 472. Biovaxys Technology holds roughly 17.0 in number of employees claiming about 4% of stocks in Biotechnology industry.
Biovaxys Book Value Per Share vs. Number Of Employees
Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Biovaxys Technology |
| = | 17 |
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Biovaxys Technology |
| = | 0.06 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Biovaxys Book Value Per Share Comparison
Biovaxys Technology is currently under evaluation in book value per share category among its peers.
Biovaxys Technology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Biovaxys Technology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Biovaxys Technology will eventually generate negative long term returns. The profitability progress is the general direction of Biovaxys Technology's change in net profit over the period of time. It can combine multiple indicators of Biovaxys Technology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
Biovaxys Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Biovaxys Technology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Biovaxys Technology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Biovaxys Technology's important profitability drivers and their relationship over time.
Use Biovaxys Technology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biovaxys Technology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biovaxys Technology will appreciate offsetting losses from the drop in the long position's value.Biovaxys Technology Pair Trading
Biovaxys Technology Corp Pair Trading Analysis
The ability to find closely correlated positions to Biovaxys Technology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biovaxys Technology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biovaxys Technology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biovaxys Technology Corp to buy it.
The correlation of Biovaxys Technology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biovaxys Technology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biovaxys Technology Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biovaxys Technology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Biovaxys Technology position
In addition to having Biovaxys Technology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Biovaxys OTC Stock
To fully project Biovaxys Technology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Biovaxys Technology Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Biovaxys Technology's income statement, its balance sheet, and the statement of cash flows.